- Fosun Pharma reported a revenue of 19.51 billion yuan for the first half of 2025.
- The company invested 1.72 billion yuan in research and development during the same period.
- Fosun Pharma’s earnings per share (EPS) stand at 64 RMB cents.
- Analyst recommendations include 5 buy ratings and 3 hold ratings, with no sell ratings.
A look at Shanghai Fosun Pharmaceutical (Group) Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a pharmaceutical company, holds promising long-term prospects based on its Smartkarma Smart Scores. With a solid Value score of 4, the company is deemed to have strong fundamentals compared to its market price. Additionally, its Dividend, Growth, Resilience, and Momentum scores all stand at 3, indicating a stable performance across these key areas. This suggests Shanghai Fosun Pharmaceutical (Group) is well-positioned for sustained growth and resilience in the pharmaceutical industry. Focusing on genetic medicines, Chinese traditional medicines, diagnostic products, and medical instruments, the company also diversifies through technology services, marketing, advertising, and import-export investments.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
